FRANKFURT AM MAIN & BOSTON–(BUSINESS WIRE)–#cytrellis—Merz Pharma has made a strategic venture investment in Cytrellis
Biosystems, a US based company developing a new class of non-surgical
products to combat sagging skin associated with aging.
Merz has joined a growing set of industry investors to back Boston-based
Cytrellis Biosystems. The investment emphasizes Merz’ strategy to
allocate venture investment focused on the areas of anti-aging, skin
rejuvenation and body shaping. And it’s the latest example of Cytrellis’
strategy to selectively attract investors who bring specific aesthetic
“As a young and innovative company with an experienced team, Cytrellis
has the potential for a successful market launch of a revolutionary
technology in the field of aesthetic medicine”, said Hans-Jörg Bergler,
Head of Global Corporate Development and member of the Merz Pharma
Board. “For Merz, the investment in Cytrellis ideally fits our current
venture strategy, which is dedicated to aesthetics.”
Cytrellis is a Boston based, clinical stage company that has been
developing an entirely new category of medical devices for the
aesthetics market. Cytrellis’ key proprietary technology removes excess
skin without invasive surgery or scarring. This technology will enable
physicians to improve sagging skin associated with aging on the face and
other areas of the body and thereby address one of the aesthetic
industry’s largest unmet needs and most valuable opportunities.
“We’re delighted to have Merz as a strategic investor,” Doug Levinson,
CEO and co-founder of Cytrellis. “From the outset, we’ve sought to
selectively engage investors that can extend Cytrellis’ access to
aesthetics industry expertise. This investment from Merz allows us to
achieve this goal. Merz has a remarkable depth of overall industry
expertise in the global aesthetics market, and a wealth of medical
device experience gained through the successful launches of Ultherapy®
In June 2015, Merz announced plans to fund investments in the global
aesthetics market through corporate venture capital. “The global
aesthetics market is growing fast and continues to present attractive
investment opportunities for promising technologies to bring real
benefit to patients and physicians,” says Bergler.
The allocation of venture capital in cooperation with other investment
partners is part of the long-term innovation and growth strategy of
Merz. Through the acquisitions of Neocutis, Anteis and BioForm Medical,
Merz has substantially expanded its presence in the aesthetics space in
recent years. Most recently, the acquisition of Ulthera, with its
advanced ultrasound technology platform, has accelerated Merz’s growth
in aesthetics and enhanced the company’s ability to provide innovative
treatments along the full continuum of care.
For more information about Merz’s Corporate Venture Capital Fund, please
For more information on Merz Pharma Group, please click here.
For more information on Cytrellis, please click here.